RxDoctor Payments Data

Natalie Amante, PA

Physician Assistant · Houston, TXNPI 1164194692

Payments from drug & device makers

$10,675in general payments, 2019–2025

Across 316 payments — averaging $33.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$5K
  • Gilead$2K
  • Madrigal Pharmaceuticals$829
  • Intercept Pharmaceuticals, Inc.$669
  • AbbVie$664
  • Ipsen Biopharmaceuticals, Inc$366
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$2,25021%
  • Travel & lodging$7327%
  • Food & beverage$7,69372%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,675 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$86,987
Medicare patients
210
Services billed
718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin26$77,967
CreonLipase/Protease/Amylase14$23,748
VemlidyTenofovir Alafenamide11$18,458
Ursodiol101$10,017
Lactulose55$1,360
Spironolactone103$1,010
Entecavir12$763
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates11$667
Pantoprazole Sodium61$600
ConstuloseLactulose17$474
Azathioprine14$428
Carvedilol62$364
Furosemide94$350
Hydroxyzine Hcl15$187
Metoclopramide Hcl12$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$5,042$77,96726 claims
AbbVieCreon$664$23,74814 claims
GileadVemlidy$1,922$18,45811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →